Cargando…
Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
BACKGROUND: The current standard of care for classical Hodgkin lymphoma (HL) is multiagent chemotherapy with or without radiation. In patients who relapse or fail to respond, additional high-dose chemotherapy with autologous hematopoietic stem cell transplantation (AHSCT) can improve progression-fre...
Autores principales: | Johnston, Patrick B., Pinter-Brown, Lauren C., Warsi, Ghulam, White, Kristen, Ramchandren, Radhakrishnan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5948762/ https://www.ncbi.nlm.nih.gov/pubmed/29774169 http://dx.doi.org/10.1186/s40164-018-0103-z |
Ejemplares similares
-
Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2022) -
Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
por: Voorhees, Timothy J, et al.
Publicado: (2020) -
Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021) -
Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review
por: Zhang, Yujie, et al.
Publicado: (2022) -
Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
por: Randall, Michael P., et al.
Publicado: (2023)